Horizon Discovery Group PLC (LON:HZD)‘s stock had its “buy” rating reissued by stock analysts at N+1 Singer in a research note issued on Tuesday. They currently have a GBX 194 ($2.53) price target on the stock. N+1 Singer’s price target points to a potential upside of 24.36% from the stock’s current price.

A number of other research analysts have also weighed in on the company. Numis Securities Ltd restated a “buy” rating and issued a GBX 260 ($3.39) price objective on shares of Horizon Discovery Group PLC in a report on Tuesday. Panmure Gordon decreased their price objective on Horizon Discovery Group PLC from GBX 270 ($3.52) to GBX 205 ($2.68) and set a “buy” rating on the stock in a report on Tuesday. Finally, Beaufort Securities restated a “speculative buy” rating on shares of Horizon Discovery Group PLC in a report on Wednesday, September 14th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Horizon Discovery Group PLC has a consensus rating of “Buy” and a consensus target price of GBX 217.25 ($2.84).

Horizon Discovery Group PLC (LON:HZD) traded down 5.45% on Tuesday, hitting GBX 156.00. 1,680,164 shares of the stock were exchanged. The stock’s 50 day moving average price is GBX 160.26 and its 200 day moving average price is GBX 160.78. The firm’s market cap is GBX 146.78 million. Horizon Discovery Group PLC has a 52-week low of GBX 125.00 and a 52-week high of GBX 188.06.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/horizon-discovery-group-plc-hzd-given-buy-rating-at-n1-singer.html

About Horizon Discovery Group PLC

Horizon Discovery (LSE: HZD) is a world-leading gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. Horizon’s proprietary gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer.

Receive News & Ratings for Horizon Discovery Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.